Thermo Fisher to Sell Microbiology Business to Astorg in $1 Billion Deal
Thermo Fisher Scientific (TMO) has agreed to sell its microbiology business to private equity firm Astorg for over $1 billion, signaling a strategic shift away from in vitro diagnostics (IVD) toward biopharma. The deal is expected to close in H2 2026 and will be discussed in the company's Q2 earnings call. The microbiology business generated $645 million in revenue in 2025.
Topics: Biopharma Divestment Life Sciences M&A Private Equity